Compelling clinical trial data and decisions from the FDA could send one, two, or all three of the biotech stocks highlighted in today’s article through the roof next year. For a look at each of these three biotech stocks and their respective catalysts – as well as a consideration of the potential pitfalls associated with each of them – CLICK HERE.
